{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:06:31Z","timestamp":1790769991612,"version":"4.1.0"},"reference-count":43,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,12,15]]},"abstract":"<jats:p>The CHK2 gene codifies for a serine\/threonine kinase that plays a central role in DNA damage response pathways. To determine the potential role of CHK2 alterations in the pathogenesis of lymphoid neoplasms we have examined the gene status, protein, and mRNA expression in a series of tumors and nonneoplastic lymphoid samples. A heterozygous Ile157Thr substitution, also present in the germ line of the patient, was detected in a blastoid mantle cell lymphoma (MCL). CHK2 protein and mRNA expression levels were similar in all types of lymphomas and reactive samples, and these levels were independent of the proliferative activity of the tumors. However, 5 tumors, one typical MCL, 2 blastoid MCLs, and 2 large cell lymphomas, showed marked loss of protein expression, including 2 samples with complete absence of CHK2 protein. These 2 lymphomas showed the highest number of chromosomal imbalances detected by comparative genomic hybridization in the whole series of cases. However, no mutations, deletions, or hypermethylation of the promoter region were identified in any of these tumors. mRNA levels were similar in cases with low and normal protein expression, suggesting a posttranscriptional regulation of the protein in these tumors. CHK2 gene and protein alterations were not related to p53 and ATMgene status. In conclusion, CHK2 alterations are uncommon in malignant lymphomas but occur in a subset of aggressive tumors independently of p53 or ATM alterations. The high number of chromosomal imbalances in tumors with complete absence of CHK2 protein suggests a role of this gene in chromosomal instability in human lymphomas.<\/jats:p>","DOI":"10.1182\/blood-2002-04-1078","type":"journal-article","created":{"date-parts":[[2002,11,26]],"date-time":"2002-11-26T18:42:38Z","timestamp":1038336158000},"page":"4602-4608","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":59,"title":["CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas"],"prefix":"10.1182","volume":"100","author":[{"given":"Frederic","family":"Tort","sequence":"first","affiliation":[{"name":"From the Laboratory of Pathology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona; the Information and Studies Service, Department of Health and Social Security; and the Department of Haematology, Hospital Clinic, Barcelona, Spain; the Cancer Epigenetics Laboratory, Molecular Pathology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain; and The Johns Hopkins Oncology Center, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Herna\u0300ndez","sequence":"additional","affiliation":[{"name":"From the Laboratory of Pathology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona; the Information and Studies Service, Department of Health and Social Security; and the Department of Haematology, Hospital Clinic, Barcelona, Spain; the Cancer Epigenetics Laboratory, Molecular Pathology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain; and The Johns Hopkins Oncology Center, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bea\u0300","sequence":"additional","affiliation":[{"name":"From the Laboratory of Pathology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona; the Information and Studies Service, Department of Health and Social Security; and the Department of Haematology, Hospital Clinic, Barcelona, Spain; the Cancer Epigenetics Laboratory, Molecular Pathology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain; and The Johns Hopkins Oncology Center, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Mart\u0131\u0301nez","sequence":"additional","affiliation":[{"name":"From the Laboratory of Pathology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona; the Information and Studies Service, Department of Health and Social Security; and the Department of Haematology, Hospital Clinic, Barcelona, Spain; the Cancer Epigenetics Laboratory, Molecular Pathology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain; and The Johns Hopkins Oncology Center, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Esteller","sequence":"additional","affiliation":[{"name":"From the Laboratory of Pathology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona; the Information and Studies Service, Department of Health and Social Security; and the Department of Haematology, Hospital Clinic, Barcelona, Spain; the Cancer Epigenetics Laboratory, Molecular Pathology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain; and The Johns Hopkins Oncology Center, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Herman","sequence":"additional","affiliation":[{"name":"From the Laboratory of Pathology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona; the Information and Studies Service, Department of Health and Social Security; and the Department of Haematology, Hospital Clinic, Barcelona, Spain; the Cancer Epigenetics Laboratory, Molecular Pathology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain; and The Johns Hopkins Oncology Center, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Puig","sequence":"additional","affiliation":[{"name":"From the Laboratory of Pathology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona; the Information and Studies Service, Department of Health and Social Security; and the Department of Haematology, Hospital Clinic, Barcelona, Spain; the Cancer Epigenetics Laboratory, Molecular Pathology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain; and The Johns Hopkins Oncology Center, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Camacho","sequence":"additional","affiliation":[{"name":"From the Laboratory of Pathology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona; the Information and Studies Service, Department of Health and Social Security; and the Department of Haematology, Hospital Clinic, Barcelona, Spain; the Cancer Epigenetics Laboratory, Molecular Pathology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain; and The Johns Hopkins Oncology Center, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montse","family":"Sa\u0301nchez","sequence":"additional","affiliation":[{"name":"From the Laboratory of Pathology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona; the Information and Studies Service, Department of Health and Social Security; and the Department of Haematology, Hospital Clinic, Barcelona, Spain; the Cancer Epigenetics Laboratory, Molecular Pathology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain; and The Johns Hopkins Oncology Center, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iracema","family":"Nayach","sequence":"additional","affiliation":[{"name":"From the Laboratory of Pathology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona; the Information and Studies Service, Department of Health and Social Security; and the Department of Haematology, Hospital Clinic, Barcelona, Spain; the Cancer Epigenetics Laboratory, Molecular Pathology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain; and The Johns Hopkins Oncology Center, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Lopez-Guillermo","sequence":"additional","affiliation":[{"name":"From the Laboratory of Pathology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona; the Information and Studies Service, Department of Health and Social Security; and the Department of Haematology, Hospital Clinic, Barcelona, Spain; the Cancer Epigenetics Laboratory, Molecular Pathology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain; and The Johns Hopkins Oncology Center, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro L.","family":"Ferna\u0301ndez","sequence":"additional","affiliation":[{"name":"From the Laboratory of Pathology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona; the Information and Studies Service, Department of Health and Social Security; and the Department of Haematology, Hospital Clinic, Barcelona, Spain; the Cancer Epigenetics Laboratory, Molecular Pathology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain; and The Johns Hopkins Oncology Center, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolors","family":"Colomer","sequence":"additional","affiliation":[{"name":"From the Laboratory of Pathology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona; the Information and Studies Service, Department of Health and Social Security; and the Department of Haematology, Hospital Clinic, Barcelona, Spain; the Cancer Epigenetics Laboratory, Molecular Pathology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain; and The Johns Hopkins Oncology Center, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Herna\u0300ndez","sequence":"additional","affiliation":[{"name":"From the Laboratory of Pathology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona; the Information and Studies Service, Department of Health and Social Security; and the Department of Haematology, Hospital Clinic, Barcelona, Spain; the Cancer Epigenetics Laboratory, Molecular Pathology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain; and The Johns Hopkins Oncology Center, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Campo","sequence":"additional","affiliation":[{"name":"From the Laboratory of Pathology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona; the Information and Studies Service, Department of Health and Social Security; and the Department of Haematology, Hospital Clinic, Barcelona, Spain; the Cancer Epigenetics Laboratory, Molecular Pathology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain; and The Johns Hopkins Oncology Center, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111822185446500_B1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0165-4608(96)00227-0","article-title":"Genetic alterations in leukemias and lymphomas: impressive progress and continuing complexity.","volume":"94","author":"Nowell","year":"1997","journal-title":"Cancer Genet Cytogenet."},{"key":"2019111822185446500_B2","first-page":"4365","article-title":"Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants.","volume":"93","author":"Bea","year":"1999","journal-title":"Blood."},{"key":"2019111822185446500_B3","first-page":"3114","article-title":"Clinicopathogenetic significance of chromosomal abnormalities in patients with blastic peripheral B-cell lymphoma. Kiel-Wien-Lymphoma Study Group.","volume":"94","author":"Schlegelberger","year":"1999","journal-title":"Blood."},{"key":"2019111822185446500_B4","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1054\/bjoc.2001.2164","article-title":"Loss of chromosome 11q21\u201323.1 and 17p and gain of chromosome 6p are independent prognostic indicators in B-cell non-Hodgkin's lymphoma.","volume":"85","author":"Stokke","year":"2001","journal-title":"Br J Cancer."},{"key":"2019111822185446500_B5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/35044005","article-title":"The DNA damage response: putting checkpoints in perspective.","volume":"408","author":"Zhou","year":"2000","journal-title":"Nature."},{"key":"2019111822185446500_B6","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1182\/blood.V84.8.2412.2412","article-title":"p53 in hematologic malignancies.","volume":"84","author":"Imamura","year":"1994","journal-title":"Blood."},{"key":"2019111822185446500_B7","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1182\/blood.V87.8.3351.bloodjournal8783351","article-title":"p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas.","volume":"87","author":"Hernandez","year":"1996","journal-title":"Blood."},{"key":"2019111822185446500_B8","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1182\/blood.V82.7.1994.1994","article-title":"p53 mutation is associated with progression in follicular lymphomas.","volume":"82","author":"Sander","year":"1993","journal-title":"Blood."},{"key":"2019111822185446500_B9","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/hmg\/7.10.1555","article-title":"ATM: from gene to function.","volume":"7","author":"Rotman","year":"1998","journal-title":"Hum Mol Genet."},{"key":"2019111822185446500_B10","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1182\/blood.V91.10.3920","article-title":"Inactivation of the ATM gene in T-cell prolymphocytic leukemias.","volume":"91","author":"Stoppa-Lyonnet","year":"1998","journal-title":"Blood."},{"key":"2019111822185446500_B11","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/nm1097-1155","article-title":"Biallelic mutations in the ATM gene in T-prolymphocytic leukemia.","volume":"3","author":"Stilgenbauer","year":"1997","journal-title":"Nat Med."},{"key":"2019111822185446500_B12","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/ng0997-96","article-title":"Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia.","volume":"17","author":"Vorechovsky","year":"1997","journal-title":"Nat Genet."},{"key":"2019111822185446500_B13","first-page":"24","article-title":"ATM mutations in B-cell chronic lymphocytic leukemia.","volume":"59","author":"Bullrich","year":"1999","journal-title":"Cancer Res."},{"key":"2019111822185446500_B14","first-page":"4552","article-title":"Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia.","volume":"58","author":"Starostik","year":"1998","journal-title":"Cancer Res."},{"key":"2019111822185446500_B15","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1073\/pnas.050400997","article-title":"Mantle cell lymphoma is characterized by inactivation of the ATM gene.","volume":"97","author":"Schaffner","year":"2000","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2019111822185446500_B16","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.V99.1.238","article-title":"ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances.","volume":"99","author":"Camacho","year":"2002","journal-title":"Blood."},{"key":"2019111822185446500_B17","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood.V99.1.300","article-title":"Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage.","volume":"99","author":"Stankovic","year":"2002","journal-title":"Blood."},{"key":"2019111822185446500_B18","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/35103059","article-title":"CHK2 kinase\u2014a busy messenger.","volume":"2","author":"Bartek","year":"2001","journal-title":"Nat Rev Mol Cell Biol."},{"key":"2019111822185446500_B19","first-page":"5718","article-title":"p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition.","volume":"61","author":"Vahteristo","year":"2001","journal-title":"Cancer Res."},{"key":"2019111822185446500_B20","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1126\/science.286.5449.2528","article-title":"Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.","volume":"286","author":"Bell","year":"1999","journal-title":"Science."},{"key":"2019111822185446500_B21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/gcc.1207","article-title":"Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors.","volume":"33","author":"Miller","year":"2002","journal-title":"Genes Chromosomes and Cancer."},{"key":"2019111822185446500_B22","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.bjc.6600131","article-title":"Analysis of CHK2 in vulval neoplasia.","volume":"86","author":"Reddy","year":"2002","journal-title":"Br J Cancer."},{"key":"2019111822185446500_B23","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/sj.onc.1205207","article-title":"Concomitant inactivation of p53 and Chk2 in breast cancer.","volume":"21","author":"Sullivan","year":"2002","journal-title":"Oncogene."},{"key":"2019111822185446500_B24","first-page":"4689","article-title":"Histological type-selective, tumor-predominant expression of a novel CHK1 isoform and infrequent in vivo somatic CHK2 mutation in small cell lung cancer.","volume":"60","author":"Haruki","year":"2000","journal-title":"Cancer Res."},{"key":"2019111822185446500_B25","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0145-2126(00)00130-2","article-title":"Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias.","volume":"25","author":"Hofmann","year":"2001","journal-title":"Leuk Res."},{"key":"2019111822185446500_B26","first-page":"8062","article-title":"Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni syndrome.","volume":"61","author":"Lee","year":"2001","journal-title":"Cancer Res."},{"key":"2019111822185446500_B27","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3109\/10428190109064610","article-title":"Analysis of the CHK2 gene in lymphoid malignancies.","volume":"42","author":"Tavor","year":"2001","journal-title":"Leuk Lymphoma."},{"key":"2019111822185446500_B28","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1182\/blood.V99.8.3075","article-title":"Mutations of Chk2 in primary hematopoietic neoplasms.","volume":"99","author":"Hangaishi","year":"2002","journal-title":"Blood."},{"key":"2019111822185446500_B29","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/S0002-9440(10)65071-7","article-title":"INK4a\/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene.","volume":"156","author":"Pinyol","year":"2000","journal-title":"Am J Pathol."},{"key":"2019111822185446500_B30","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood.V89.1.272","article-title":"Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas.","volume":"89","author":"Pinyol","year":"1997","journal-title":"Blood."},{"key":"2019111822185446500_B31","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/(SICI)1098-2744(199804)21:4<251::AID-MC4>3.0.CO;2-N","article-title":"Ki-ras gene mutations and absence of p53 gene mutations in spontaneous and urethane-induced early lung lesions in CBA\/J mice.","volume":"21","author":"Cazorla","year":"1998","journal-title":"Mol Carcinog."},{"key":"2019111822185446500_B32","doi-asserted-by":"crossref","first-page":"9821","DOI":"10.1073\/pnas.93.18.9821","article-title":"Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.","volume":"93","author":"Herman","year":"1996","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2019111822185446500_B33","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.289.5478.359a","article-title":"Screening hCHK2 for mutations.","volume":"289","author":"Sodha","year":"2000","journal-title":"Science."},{"key":"2019111822185446500_B34","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1046\/j.1365-2141.2000.02352.x","article-title":"The use of real-time quantitative polymerase chain reaction and comparative genomic hybridization to identify amplification of the REL gene in follicular lymphoma.","volume":"111","author":"Goff","year":"2000","journal-title":"Br J Haematol."},{"key":"2019111822185446500_B35","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood.V97.2.572","article-title":"Hemizygous p16(INK4A) deletion in pediatric acute lymphoblastic leukemia predicts independent risk of relapse.","volume":"97","author":"Carter","year":"2001","journal-title":"Blood."},{"key":"2019111822185446500_B36","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1054\/bjoc.2001.1858","article-title":"Mutation analysis of the CHK2 gene in families with hereditary breast cancer.","volume":"85","author":"Allinen","year":"2001","journal-title":"Br J Cancer."},{"key":"2019111822185446500_B37","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1038\/sj.onc.1204811","article-title":"Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway.","volume":"20","author":"Falck","year":"2001","journal-title":"Oncogene."},{"key":"2019111822185446500_B38","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/35071124","article-title":"The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis.","volume":"410","author":"Falck","year":"2001","journal-title":"Nature."},{"key":"2019111822185446500_B39","doi-asserted-by":"crossref","first-page":"5897","DOI":"10.1038\/sj.onc.1204746","article-title":"Chk2 tumour suppressor protein in human spermatogenesis and testicular germ-cell tumours.","volume":"20","author":"Bartkova","year":"2001","journal-title":"Oncogene."},{"key":"2019111822185446500_B40","first-page":"5362","article-title":"Reduced expression and impaired kinase activity of a Chk2 mutant identified in human lung cancer.","volume":"61","author":"Matsuoka","year":"2001","journal-title":"Cancer Res."},{"key":"2019111822185446500_B41","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1074\/jbc.M009727200","article-title":"Characterization of tumor-associated Chk2 mutations.","volume":"276","author":"Wu","year":"2001","journal-title":"J Biol Chem."},{"key":"2019111822185446500_B42","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev.immunol.15.1.177","article-title":"The genetic defect in ataxia-telangiectasia.","volume":"15","author":"Lavin","year":"1997","journal-title":"Annu Rev Immunol."},{"key":"2019111822185446500_B43","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0092-8674(01)00227-6","article-title":"Suppression of spontaneous chromosomal rearrangements by S phase checkpoint functions in Saccharomyces cerevisiae.","volume":"104","author":"Myung","year":"2001","journal-title":"Cell."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/13\/4602\/1255307\/h82402004602.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/13\/4602\/1255307\/h82402004602.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T03:19:09Z","timestamp":1574133549000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/100\/13\/4602\/106052\/CHK2decreased-protein-expression-and-infrequent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12,15]]},"references-count":43,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2002,12,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-04-1078","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,12,15]]}}}